Prolonged Survival of Neutrophils Induced by Tumor-Derived G-CSF/GM-CSF Promotes Immunosuppression and Progression in Laryngeal Squamous Cell Carcinoma

  • 0Department of Otolaryngology, Shanghai Key Clinical Disciplines of otorhinolaryngology, Eye Ear Nose & Throat Hospital, Fudan University, Shanghai, 200025, P. R. China.

Summary

This summary is machine-generated.

Tumor-associated neutrophils (TANs) in laryngeal cancer survive longer due to tumor factors, suppressing immune cells. Blocking these factors may offer a new cancer therapy strategy.

Area Of Science

  • Oncology
  • Immunology
  • Cell Biology

Background

  • Tumor-associated neutrophils (TANs) are crucial in tumor progression and exhibit prolonged survival.
  • The mechanisms behind TANs' extended lifespan and their role in laryngeal squamous cell carcinoma (LSCC) are not fully understood.

Purpose Of The Study

  • To investigate the mechanisms of prolonged TAN survival in LSCC.
  • To determine the impact of extended TAN survival on the tumor microenvironment and patient prognosis.
  • To explore potential therapeutic strategies targeting neutrophil survival.

Main Methods

  • Analysis of TAN apoptosis in LSCC.
  • Investigation of signaling pathways (PI3K-AKT) and protein expression (Mcl-1, Caspase-3) involved in neutrophil survival.
  • Assessment of aged CXCR4+ neutrophil accumulation and immunosuppressive properties.
  • Evaluation of TAN effects on CD8+ T cell function and LSCC tumor growth in vitro and in vivo.
  • Experimental blockade of G-CSF and GM-CSF signaling.

Main Results

  • Tumor-derived G-CSF and GM-CSF significantly delay TAN apoptosis via PI3K-AKT activation, Mcl-1 upregulation, and Caspase-3 downregulation.
  • Prolonged TAN survival leads to accumulation of immunosuppressive CXCR4+ neutrophils, correlating with poor prognosis.
  • Extended TAN survival enhances their ability to suppress CD8+ T cells, promoting LSCC progression.
  • Blocking G-CSF and GM-CSF reversed these effects.

Conclusions

  • Pathologically prolonged neutrophil survival in LSCC impairs CD8+ T cell immunity.
  • Targeting neutrophil survival presents a potential therapeutic strategy for LSCC and other tumors.